DWTX insider filings
Dogwood Therapeutics, Inc. — 27 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-27. Screen DWTX transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Sealbond Ltd — Director, 10% owner & Conjoint Inc. — Director, 10% owner & CK Life Sciences Intl (Holdings) Inc — Director, 10% owner | 1 | — | — | 1 |
Recent insider filings — Dogwood Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-27 | 4 | Sealbond Ltd — Director, 10% owner Conjoint Inc. — Director, 10% owner CK Life Sciences Intl (Holdings) Inc — Director, 10% owner | Grant/award (A): 4,098,360 @ $1.22 | EDGAR |
| 2026-06-17 | 4 | Keefer David R — Director | Grant/award (A): 16,800 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | De La Rosa Abel — Director | Grant/award (A): 16,800 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Whitley Richard James — Director | Grant/award (A): 16,800 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Thomas John C — Director | Grant/award (A): 16,800 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Duncan Gregory Scott — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 330,000 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Gendreau Roger Michael — CHIEF MEDICAL OFFICER | Grant/award (A): 82,500 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Grosswald Ralph — SVP OF OPERATIONS | Grant/award (A): 82,500 (derivative) @ $0 | EDGAR |
| 2026-03-06 | 4 | Walsh Angela — Chief Financial Officer | Grant/award (A): 82,500 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Duncan Gregory Scott — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 460,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Gendreau Roger Michael — CHIEF MEDICAL OFFICER | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Grosswald Ralph — SVP OF OPERATIONS | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Walsh Angela — Chief Financial Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Sealbond Ltd — Director, 10% owner Conjoint Inc. — Director, 10% owner CK Life Sciences Intl (Holdings) Inc — Director, 10% owner | Conversion (C): 21,610,950 · Conversion (C): 2,842,638 · Conversion (C): 2,161.09 (derivative) @ $0 · Conversion (C): 284.26 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Gendreau Roger Michael — CHIEF MEDICAL OFFICER | Grant/award (A): 12,075 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Grosswald Ralph — SVP OF OPERATIONS | Grant/award (A): 12,075 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Duncan Gregory Scott — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Keefer David R — Director | Grant/award (A): 2,362 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Walsh Angela — Chief Financial Officer | Grant/award (A): 12,075 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | De La Rosa Abel — Director | Grant/award (A): 2,362 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Whitley Richard James — Director | Grant/award (A): 2,362 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | Thomas John C — Director | Grant/award (A): 2,362 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Keefer David R — Director | Grant/award (A): 210 (derivative) @ $0 · Grant/award (A): 210 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | De La Rosa Abel — Director | Grant/award (A): 210 (derivative) @ $0 · Grant/award (A): 210 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Whitley Richard James — Director | Grant/award (A): 210 (derivative) @ $0 · Grant/award (A): 210 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Thomas John C — Director | Grant/award (A): 210 (derivative) @ $0 · Grant/award (A): 210 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | CK Life Sciences Intl (Holdings) Inc — Director, 10% owner | Grant/award (A): 284.26 (derivative) @ $7.01 | EDGAR |
Recent 8-K events — Dogwood Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-18 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DWTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs